Clinical trials: Hemostatic Disorders
Benign or Malignant Disease Indicated for Colectomy
Harmonic ACE®+7 Shears in Laparoscopic Colectomy
This is a prospective, non-randomized, single arm, multicenter, observational study to assess the initial clinical experience with the Harmonic ACE®+7 Shears by evaluating vessel sealing during laparoscopic colectomy.
- Trial name
- NCT02248246
- Testing
- Harmonic ACE®+7 Shears
- Where
- 4 sites in United States, Belgium and 1 more
- Volunteers
- 40 people
- Sponsor
- Ethicon Endo-Surgery
Multiple Myeloma
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents.
- Trial name
- ANCHOR (NCT03481556)
- Testing
- Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib
- Where
- 16 sites in United States, Czechia and 2 more
- Volunteers
- 56 people
- Sponsor
- Oncopeptides AB
Relapsed and Refractory Multiple Myeloma
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.
- Trial name
- NCT03029234
- Testing
- Dexamethasone, Carfilzomib
- Where
- 17 sites in China
- Volunteers
- 126 people
- Sponsor
- Amgen
Multiple Myeloma
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
The study involves the use of a targeted form of radiation, in addition to standard high dose chemotherapy and stem cell transplant for multiple myeloma.
- Trial name
- NCT01207765
- Testing
- indium-111-ibritumomab tiuxetan, 90Y Zevalin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Tufts Medical Center
Myelodysplastic Syndrome, Hodgkin's Lymphoma
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without a human leukocyte-antigen (HLA) tissue-matched sibling and graft-versus-host disease (GVHD)…
- Conditions
- Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia
- Trial name
- NCT00520130
- Testing
- Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00530816
- Testing
- carfilzomib
- Where
- 30 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Amgen
Multiple Myeloma in Relapse
Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse
In Multiple Myeloma, an adult hematological malignancy, mainly located in the Bone Marrow (BM), dramatic recent progresses have been observed, thanks to new agents (proteasome inhibitors and IMIDs).
- Trial name
- TOMMY (NCT01794572)
- Testing
- Total Bone Marrow Irradiation (TBMI) 8 Gy, Total Bone Marrow Irradiation (TBMI) 10 Gy, Total Bone Marrow Irradiation (TBMI): 12 Gy
- Where
- 8 sites in France
- Volunteers
- 13 people
- Sponsor
- Institut Cancerologie de l'Ouest
Hemophilia A
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.
- Trial name
- GENEr8-3 (NCT04323098)
- Testing
- valoctocogene roxaparvovec
- Where
- 12 sites in United States, Australia and 2 more
- Volunteers
- 22 people
- Sponsor
- BioMarin Pharmaceutical
Hemostasis, General Surgery
A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
The Study investigates a new product, sFilm-FS, aimed to help controlling body fluid leakage in general surgery procedures, proposing its use as an adjunct to hemostasis and/or sealing.
- Trial name
- NCT04660721
- Testing
- sFilm-FS, TACHOSIL®
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 33 people
- Sponsor
- Sealantium Medical Ltd.
Multiple Myeloma
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
This is a multi-center, open-label, non-randomized study. Patients will receive ASP7487 (OSI-906) in combination with bortezomib and dexamethasone.
- Trial name
- NCT01672736
- Testing
- ASP7487, Velcade, Dexamethasone
- Where
- 6 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- University Health Network, Toronto
Multiple Myeloma
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in…
- Trial name
- UPFRONT (NCT00507416)
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- 235 sites in United States, Puerto Rico
- Volunteers
- 502 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Trauma, Hemorrhagic Shock
Control of Major Bleeding After Trauma Study
Bleeding is the most avoidable cause of death in trauma patients. Up to one-third of severely injured trauma patients are found to be coagulopathic and forty percent of the mortality following severe injury is due to…
- Trial name
- COMBAT (NCT01838863)
- Testing
- Type AB plasma, Crystalloid fluid (standard of care for resuscitation)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Denver Health and Hospital Authority
Multiple Myeloma
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment.
- Trial name
- NCT00349778
- Testing
- Cyclophosphamide, Etoposide, Melphalan
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Stanford University
Multiple Myeloma
CT Antigen TCR-Engineered T Cells for Myeloma
This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
- Trial name
- NCT01892293
- Testing
- Treatment with NY-ESO-1c259-modified T cells
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adaptimmune
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This phase II trial studies how well donor peripheral blood stem cell (PBSC) transplant works in treating patients with hematologic malignancies.
- Conditions
- Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01028716
- Testing
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Fred Hutchinson Cancer Center
Waldenstrom Macroglobulinemia
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment naïve or relapsed/refractory…
- Trial name
- NCT04062448
- Testing
- Ibrutinib, Rituximab
- Where
- 9 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Janssen Pharmaceutical K.K.
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Trial name
- NCT01760655
- Testing
- Fludarabine phosphate, Busulfan, Total-Body Irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Multiple Myeloma
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
Primary Objectives: Phase I: To evaluate safety and tolerability of isatuximab in Japanese participants with relapsed and refractory multiple myeloma.
- Trial name
- Islands (NCT02812706)
- Testing
- Isatuximab SAR650984
- Where
- 13 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Sanofi
Multiple Myeloma
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune…
- Trial name
- PCV13 (NCT01852591)
- Testing
- PCV 13
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.